Q: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
 The Molecule has the SMILES CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.
Answer: Approved
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.